At the end of the latest market close, Oncolytics Biotech Inc. (ONCY) was valued at $3.94. In that particular session, Stock kicked-off at the price of $3.97 while reaching the peak value of $4.33 and lowest value recorded on the day was $3.91. The stock current value is $4.19.
Recently in News on April 5, 2021, Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors. Webinar will take place Monday April 12, 2021 at 2:00 pm ET. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Oncolytics Biotech Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.70 on 02/17/21, with the lowest value was $2.25 for the same time period, recorded on 01/05/21.
Oncolytics Biotech Inc. (ONCY) full year performance was 188.97%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Oncolytics Biotech Inc. shares are logging -10.85% during the 52-week period from high price, and 227.34% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.28 and $4.70.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1733630 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Oncolytics Biotech Inc. (ONCY) recorded performance in the market was 76.05%, having the revenues showcasing 79.06% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 216.54M, as it employees total of 25 workers.
Oncolytics Biotech Inc. (ONCY) in the eye of market guru’s
During the last month, 5 analysts gave the Oncolytics Biotech Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.89, with a change in the price was noted +2.03. In a similar fashion, Oncolytics Biotech Inc. posted a movement of +93.98% for the period of last 100 days, recording 1,820,783 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ONCY is recording 0.02 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.01.
Oncolytics Biotech Inc. (ONCY): Stocks Technical analysis and Trends
Raw Stochastic average of Oncolytics Biotech Inc. in the period of last 50 days is set at 78.57%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 89.09%. In the last 20 days, the company’s Stochastic %K was 78.96% and its Stochastic %D was recorded 74.72%.
If we look into the earlier routines of Oncolytics Biotech Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 76.05%. Additionally, trading for the stock in the period of the last six months notably improved by 142.20%, alongside a boost of 188.97% for the period of the last 12 months. The shares increased approximately by 15.11% in the 7-day charts and went down by 56.34% in the period of the last 30 days. Common stock shares were driven by 79.06% during last recorded quarter.